Search Bar & Filters
Found 11 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the safety and effects of a new drug called NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction HFpEF or Heart Failure with mildly reduced Ejection Fraction HFmrEF who also have excess body weight. This study compares NNC0487-0111 against a placebo to determine if it is safe and effective for treating these heart conditions in people with obesity. The study is a randomized, controlled trial conducted by Novo Nordisk AS. Participants will receive either NNC0487-0111 or a placebo by subcutaneous injection once a week. The study drug dose may increase over time for those receiving NNC0487-0111. Treatment assignment is random, and the study includes a parallel design with two groups one receiving the experimental drug and one receiving placebo. The treatment period and monitoring last up to 165 weeks. During the study, participants will be monitored for heart failure events, cardiovascular death, hospital visits related to heart failure, and other major cardiovascular outcomes. They will complete questionnaires about their heart failure symptoms and quality of life. Kidney function will also be assessed in some participants. Safety and effectiveness will be evaluated throughout the study period, which can last over three years, with regular visits for injections and assessments.
Actively Recruiting
Researchers are evaluating camizestrant compared to standard endocrine therapy in patients with ER-positive, HER2-negative early breast cancer who have an intermediate or high risk of disease recurrence. This Phase III open-label study includes patients who have completed definitive locoregional therapy, with or without chemotherapy, and have received standard adjuvant endocrine therapy for at least 2 years and up to 5 years. The study aims to determine if camizestrant improves invasive breast cancer-free survival and other important outcomes over a long-term follow-up. Participants will be randomly assigned to receive either camizestrant orally or continue standard endocrine therapy chosen by their doctor, which may include aromatase inhibitors like exemestane, letrozole, anastrozole, or tamoxifen. Treatment in both groups will last for up to 60 months. The study allows prior use of CDK46 inhibitors and includes an open-label design where both participants and researchers know the assigned treatment. During the study, participants will be monitored with assessments including survival outcomes, disease-free survival, relapse-free survival, and overall survival for up to 10 years from the last patient randomized. Safety will be tracked through adverse event reporting, laboratory and vital signs tests, and symptom questionnaires measuring arthralgia, hot flushes, vaginal dryness, and quality of life. Pharmacokinetics will be studied up to 6 months after treatment starts. The total duration of participation can extend over many years to capture long-term results.
Actively Recruiting
Researchers are evaluating a surgical approach called Complete Mesocolic Excision with Central Vascular Ligation CMECVL compared to standard right hemicolectomy in patients with malignant tumors located in the right or proximal transverse colon. This Italian randomized controlled trial focuses on patients with stage II-IV colon cancer and aims to determine differences in disease-free survival as the primary outcome. The study also looks at safety, oncologic results, surgical quality, and quality of life as secondary outcomes. Participants will be randomly assigned to one of two groups one undergoing the conventional non-CME right hemicolectomy and the other receiving the CMECVL procedure. The CMECVL technique involves removing lymphovascular tissue at the origin of supplying vessels and preserving the mesocolon as an intact envelope. Various surgical approaches, including open, laparoscopic, or robotic surgery, are allowed. Surgeons decide the type of anastomosis and drain placement. The trial plans to enroll 416 patients over one and a half years, with five years of postoperative follow-up. During the study, patients will be monitored at 1, 4, 12, 24, 36, and 60 months after surgery. Researchers will collect demographic, baseline, perioperative, and postoperative data, evaluating outcomes such as disease-free survival at three years, safety measures including operative time and complications, overall survival, and quality of life. The total study duration is expected to be six and a half years, providing both short- and long-term information on these surgical methods.
Actively Recruiting
Researchers are evaluating the clinical characteristics and procedural outcomes of patients receiving permanent cardiac pacing to treat various heart rhythm disorders. This observational study compares the effectiveness and safety of different device implantation methods used in routine clinical practice, including the contribution of advanced non-fluoroscopic anatomical and electrophysiological mapping systems. The study focuses on patients over 18 years old who require a pacemaker or intracardiac defibrillator implant following European Society of Cardiology guidelines. The study includes several types of cardiac pacing approaches conventional right ventricular pacing, conduction system pacing such as His bundle or left bundle branch area pacing, cardiac resynchronization therapy CRT with biventricular or left ventricular pacing, epicardial pacing often done during cardiac surgery, and leadless pacing via a percutaneous femoral vein approach. Each method involves implantation of a device connected to cardiac leads positioned in specific heart locations, with vascular access through veins like the cephalic, axillary, or subclavian. Electrical parameters such as pacing threshold and sensing are measured to ensure device stability before final placement. Participants will be followed for up to 120 months with clinical and procedural data collected, including assessments of device efficacy and safety at 30 days, 6 months, and 12 months. Outcome measures include stable electrical device performance, absence of cardiovascular hospitalizations or death, and monitoring for heart failure or arrhythmia events. The study also tracks procedural times, radiation exposure, and complications such as infections or lead dislocations. This long-term observation aims to understand the benefits and risks of various pacing strategies in real-world settings.
Actively Recruiting
Researchers are studying patients experiencing arrhythmic storm, a serious heart condition characterized by frequent and sustained ventricular arrhythmias that do not respond to standard antiarrhythmic drugs. This international multicenter observational study aims to evaluate the safety and effectiveness of Percutaneous Stellate Ganglion Block PSGB in reducing arrhythmic relapses in such emergency cases. The study is coordinated by Fondazione IRCCS Policlinico San Matteo of Pavia, Italy, and addresses a gap in large-scale data on this procedure. Participants who meet the criteria will receive PSGB using either the anatomical or echo-guided approach. Depending on patient needs, the procedure may involve a single anesthetic injection or continuous anesthetic infusion via a catheter connected to a pump. The study compares the number of arrhythmic events and defibrillations before and after PSGB treatment and notes any complications occurring within 12 hours post-procedure. During participation, patients will be monitored closely for arrhythmic relapses using defibrillation counts and anti-tachycardia pacing data. Complications such as hematomas, vascular injuries, and nerve damage will be recorded. Data are collected using a secure electronic system, with effectiveness measured by arrhythmic event reduction in the 12 hours following PSGB compared to the 12 hours prior. The study plans to enroll patients over several years with ongoing safety and outcome evaluations.
Actively Recruiting
Researchers are evaluating a structured multidisciplinary approach called iABC to improve the management of elderly patients with atrial fibrillation AF who have multiple long-term health conditions. This study aims to compare the iABC approach with usual clinical care to see if it leads to better clinical outcomes and quality of life. The iABC strategy focuses on three key areas preventing stroke with appropriate anticoagulation, improving symptom control, and optimizing treatment of related heart and other health conditions. The trial is conducted across several European countries including Bulgaria, Denmark, Italy, Romania, Serbia, and Spain. The study is designed as a cluster randomized trial where participating centers are assigned either to implement the iABC platform or continue their usual care practices. The iABC platform combines an educational program, a healthy diet and physical activity plan, guideline-based medication management, and regular patient reassessments. Doctors using iABC can monitor patient data and provide personalized advice on treatments and lifestyle throughout the study. Centers in the control group will manage patients according to their local standard care guidelines. Participants will be followed for at least 12 months to assess the impact of iABC on outcomes such as unplanned hospitalizations, stroke and cardiovascular events, physical activity levels, patient engagement, and medication adherence. The study includes regular data collection to monitor these factors and assess adherence to the iABC care pathway. This approach aims to provide clear evidence about whether a holistic, integrated care model can improve health and quality of life in older adults with AF and multiple health issues.
Actively Recruiting
Researchers are studying mild traumatic brain injury TBI, a common reason for emergency department visits. The study focuses on how brain computed tomography CT scans are used to detect brain injuries in patients with mild TBI. It aims to analyze the variability of CT scan use across Italian emergency departments, evaluate existing scoring systems that guide CT use, and develop a new model to better predict patient outcomes after mild head trauma. The study observes adult patients with mild TBI who present to emergency departments. Researchers will collect data on CT scan use and assess the accuracy of current clinical decision tools like the Canadian CT Head Rule and NICE guidelines. They will then work to create an improved scoring system to help doctors decide when CT scans are necessary, aiming to reduce unnecessary radiation exposure and healthcare costs. Participants will be monitored from September 2025 through August 2027 with data collected on CT scan usage and patient outcomes. The study will validate existing scores between September 2026 and August 2027 and develop a new predictive score by August 2027. Researchers will review patient data, including Glasgow Coma Scale scores, to measure how well the new tool predicts clinically relevant events. The total study duration spans from January 2026 to August 2027.
Actively Recruiting
Researchers are studying acute intoxications in children to better understand how often these poisonings occur and what social and care factors contribute to them. This research focuses on children from 1 month to 16 years old who experience acute intoxication, aiming to improve future national diagnostic and treatment approaches. The study is a prospective, multicenter observational cohort conducted by AMIETOX at Poison Control Centres and paediatric emergency rooms. The study observes children who come to emergency rooms or contact Poison Control Centres due to acute intoxication, defined as exposure to harmful substances either by toxic nature or improper use. It does not involve specific treatments or interventions but records data over approximately one year to assess incidence and prevalence. This observational approach allows researchers to collect real-world information about poisoning cases in paediatric settings. Participants will be monitored through their visits or calls to study centers, with data collected on the nature and circumstances of the intoxications. Researchers will measure how often these poisonings occur and how widespread they are among children in the study. The study involves no active treatment or placebo, focusing instead on gathering information to inform better care strategies. Participation lasts about one year, during which safety and outcomes are tracked through standard care processes.
Actively Recruiting
Researchers are evaluating the use of robotic versus laparoscopic surgery for treating diverticular disease, a condition affecting the colon. This prospective multicenter study aims to determine if robotic colectomy reduces the need to switch to open surgery compared to laparoscopic surgery. The study also examines differences in complications during and after surgery, hospital stay length, and patient outcomes up to one year after treatment. The study includes two groups of patients undergoing elective or delayed urgent minimally invasive surgery for left-sided diverticular disease. One group receives robotic left colectomy, and the other undergoes laparoscopic left colectomy, both considered standard care depending on surgeon or institutional experience. Data collection spans one year with follow-up extending to two years to monitor surgical outcomes and recovery. Participants will provide information on their health and surgical experiences through a secure database accessible via mobile devices. Researchers will track demographics, surgical details, complications within 30 days after surgery, time to return to work, and one-year post-surgery outcomes. The primary outcome is the rate of conversion to open surgery within one year, with secondary measures including operative time, complications, hospital stay duration, and overall recovery. The study follows ethical standards and plans to share findings through scientific publications and presentations.
Actively Recruiting
Researchers are evaluating the long-term safety, performance, and functional outcomes of the Indigo Aspiration System for treating pulmonary embolism PE. This observational study focuses on patients with acute PE and aims to gather real-world data on how well the device works and its safety over time. Participants receive frontline treatment with the Indigo Aspiration System as part of their standard care for acute PE. The study monitors patients for safety events within 48 hours after the procedure and assesses heart function by measuring the right ventricle to left ventricle ratio. Quality of life and functional outcomes are evaluated at 90 days, along with longer-term monitoring for serious device-related events and mortality up to one year and 30 days respectively. During the study, participants will undergo diagnostic imaging and clinical assessments to track their recovery and the effects of the device. Researchers will collect data on adverse events, quality of life questionnaires, exercise capacity tests, and symptom scales. The total participation lasts up to several months, including follow-up visits to ensure comprehensive monitoring of safety and function after treatment.
1-10 of 11
1